Noubar Afeyan, PhD
Founder and Chairman
Dr. Afeyan is Managing Partner and CEO of Flagship Ventures, a firm that manages over $900 million in early-stage funds across the sectors of Therapeutics, Health Technologies and Sustainability/Clean Technology. A technologist, entrepreneur and venture capitalist, Dr. Afeyan has co-founded and helped build over 25 successful life science and technology start-ups during the past two decades. In addition to Joule, he is a director and co-founder of Flagship portfolio companies Affinnova, BG Medicine, Ensemble Therapeutics, LS9, Midori, Moderna Therapeutics and Pronutria. Previously he was a member of the founding team, director and investor in several successful ventures including Chemgenics Pharmaceuticals, Color Kinetics, Antigenics, EXACT Sciences and Adnexus Therapeutics.
Mr. Akhanov is President and CEO of Rusnano USA, Inc., the US office for the Moscow-headquartered Rusnano, a $10 billion state-backed private equity and venture capital firm. Previously, Mr. Akhanov acted as the Head of the Russian Federal Energy Agency, implementing government policy and managing Russian state assets in the oil & gas, coal and electricity sectors. He has extensive experience in strategic planning, corporate finance and investor relations.
Graham Allison, PhD
Dr. Allison is Director of the Belfer Center for Science and International Affairs at Harvard University, and a leading analyst of US national security and defense policy. As Assistant Secretary of Defense in the first Clinton Administration, Dr. Allison received the Defense Department's highest civilian award, the Defense Medal for Distinguished Public Service, for "reshaping relations with Russia, Ukraine, Belarus, and Kazakhstan to reduce the former Soviet nuclear arsenal." He was also Special Advisor to the Secretary of Defense under President Reagan. Dr. Allison has served as a Director of the Getty Oil Company, Natixis, Loomis Sayles, Hansberger, Taubman Centers, Inc., and Belco Oil and Gas, as well as a member of the Advisory Boards of Chase Bank, Chemical Bank, Hydro-Quebec, and the International Energy Corporation.
Brian Baynes, PhD
Board Member, Chief Executive Officer
Brian joined Flagship Ventures in 2004 and focuses on innovating, leading, and investing in new ventures in life sciences and sustainability. He is Founder and Chairman of Midori Renewables, which is commercializing a novel technology for production of renewable sugar and fiber. He is also a co-founder and CEO of Flagship portfolio company Celexion, a company applying synthetic biology to problems in pharmaceuticals and industrial biotechnology. Previously, Brian co-founded portfolio company Codon Devices and worked closely with Adnexus, BG Medicine, and Epitome Biosystems. Prior to joining Flagship, Brian was an engineer at ExxonMobil, and a Director in the MIT School of Chemical Engineering Practice at Mitsubishi Chemicals and General Mills. He holds a BChE from the University of Delaware and a PhD from MIT, both in chemical engineering.
Mr. Brady is currently Executive Chairman of Lux Research and Monolith Materials, and CEO, Director and Co-Founder of Enchi Corporation, an industrial biotechnology company developing advanced organisms to convert cellulosic biomass to fuels. Mr. Brady previously served as President, Chief Executive Officer and a Director of Mascoma Corporation, a leading industrial biotechnology company. Mascoma’s bioconversion products produced over 3 billion gallons of biofuels prior to a successful sale to Lallemand Corporation. Prior to Mascoma, Mr. Brady was Executive Vice President of Cabot Corporation, a $3 BN specialty chemical company. Throughout his twenty-three year experience, Mr. Brady held numerous positions at Cabot in the United States and Asia, including General Manager of the $2 Billion Carbon Black business which operated 23 manufacturing plants in 17 countries. Under his leadership, the business completed significant expansions in China and Brazil, and executed a major global initiative in energy efficiency. In addition, he led the commercialization of two start-up businesses at Cabot in ink jet colorants and elastomer composites.
Ms. Dorsa is Executive Vice President and CFO of Public Service Enterprise Group (NYSE: PEG), a publicly traded diversified energy company with annual revenues of more than $11 billion. She previously served as Senior Vice President, Global Human Health, Strategy and Integration at Merck & Co., where she spent more than 20 years in various financial positions, including Vice President and Treasurer. She also held the role of Senior Vice President and CFO at Avaya, Inc., during which time she supported the company throught its acquisition by private equity. Earlier in her career, Ms. Dorsa worked for Mayor Ed Koch of the City of New York promoting economic development in midtown Manhattan. In addition to her board role at Joule, she currently serves on the board of Biogen Idec (NASDAQ: BIIB).
Mr. Grigorian is an internationally experienced investment banker and investor. Most recently, he led the merger of the leading Russian independent investment bank, Troika Dialog, with Sberbank, the country’s largest financial institution, and the follow-on integration across all business lines. In addition, he had run a leading real estate private equity fund, as well as various proprietary cross-border projects and transactions. Mr. Grigorian began his investment banking career in the mid 1990s with Salomon Brothers, then continued at Goldman Sachs. He has worked in London, Frankfurt and Moscow.
Stelios Papadopoulos, PhD
Dr. Papadopoulos is co-founder and chairman of Exelixis, a development-stage biotech company focused on novel small molecule therapeutics for the treatment of cancer and other serious diseases. He retired as Vice Chairman of Cowen & Co. in August 2006 after six years as an investment banker with the firm, where he focused on the biotechnology and pharmaceutical sectors. Prior to joining Cowen & Co., Dr. Papadopoulos spent 13 years as an investment banker at PaineWebber, where he was most recently Chairman of PaineWebber Development Corp., a subsidiary focusing on biotechnology. In addition to Joule, he is a co-founder and board member of Anadys Pharmaceuticals and Cellzome, and also serves on the boards of BG Medicine, Regulus Therapeutics and Biogen Idec.
Mr. Tchuruk is the former chairman and CEO of Alcatel and Total SA. He started his career in the Mobil Corporation, where he held various management positions in France and the US from 1964 to 1979, then with Rhône-Poulenc, where he was named CEO in 1983. He served as chairman and CEO of CDF-Chimie/Orkem from 1986 to 1990, then as chairman and CEO of TOTAL, one of the world's leading oil and gas companies, from 1990 to 1995. In 1995, he became chairman and CEO of Alcatel, a global telecommunications company, leading Alcatel’s merger with Lucent Technologies in 2006. Following the merger, he served as chairman of Alcatel-Lucent until 2008. He has served on the boards of many companies, including Thales Avionics Inflight Systems, LLC, Institut Pasteur, Société Genérale and Ecole Polytechnique.
Mr. Vardanyan is the President of LLC VARDANYAN, BROITMAN AND PARTNERS, and was formerly Chairman of Troika Dialog until its merger with Sberbank in January 2012. He has played a prominent role in Russia's fledgling capital markets, and previously established Troika as the pre-eminent local investment bank in Russia and other major CIS countries. Mr. Vardanyan is Chairman or board member of numerous organizations, including OJSC Rosgosstrakh (the major insurance player in the Russian market), Ameriabank (the leading bank in Armenia), OJSC KAMAZ (the largest truck manufacturer in Eastern Europe), CJSC SIBUR Holding (the leader of petrochemistry in Russia and Eastern Europe), and OJSC United Grain Company (one of Russia's largest infrastructure and trading companies).